News of Note—Takeda grabs approval, repackager recalls 40 lots of losartan

Woman typing on computer
(Max Pixel CC0)

> Drug repackager Legacy Pharmaceutical Packaging is recalling 40 repackaged lots of Losartan Tablets USP 25 mg, 50 mg and 100 mg to the consumer level because they were made with an API in which the impurity N-Nitroso N-Methyl 4-amino butyric acid was detected. Release  

> Cambrex has completed an update at its R&D lab in Milan, including the installation of a 12,000-liter reactor into one of its cGMP manufacturing facilities at the site. Release

> CDMO Ajinomoto Bio-Pharma Services  is adding a new fully isolated, nested flexible fill line, installing automated packaging and labeling equipment and upgrading its continuous flow and small molecule API manufacturing capabilities at a plant in San Diego as part of a $100 million  investment in its manufacturing network. Release

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> The FDA has approved a submission from Takeda to produce Flexbumin human albumin solution at the $1 billion plant in Covington, Georgia, that it picked up in its buyout of Shire. Report

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.